1293284-52-2

Basic information

• Product Name: 4-chloro-2-(2H-1,2,3-triazol-2-yl)benzoic acid
• Synonyms: 4-chloro-2-(2H-1,2,3-triazol-2-yl)benzoic acid
• CAS NO: 1293284-52-2
• Molecular Weight: 223.619
• Mol File: 1293284-52-2.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: 4-chloro-2-(2H-1,2,3-triazol-2-yl)benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-chloro-2-(2H-1,2,3-triazol-2-yl)benzoic acid(1293284-52-2)
• EPA Substance Registry System: 4-chloro-2-(2H-1,2,3-triazol-2-yl)benzoic acid(1293284-52-2)

Safety Data

• Hazardous Substances Data: 1293284-52-2(Hazardous Substances Data)

Upstream product

• 288-36-8 1,2,3-triazole 
• 13421-13-1 4-chloro-2-iodobenzoic acid 

Downstream Products

• 1597523-93-7 (4-chloro-2-[1,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxyphenyl)-[1,2,4]oxadiazol-3-yl]pyrrolidin-1-yl}methanone 
• 1597522-50-3 (5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxyphenyl)-[1,2,4]oxadiazol-3-yl]pyrrolidin-1-yl}methanone 
• 1597519-98-6 (4-chloro-2-[1,2,3]triazol-2-ylphenyl)-{(S)-2-[3-(2-trifluoromethoxyphenyl)-[1,2,4]oxadiazol-5-yl]pyrrolidin-1-yl}methanone 

Relevant articles and documents

From Oxadiazole to Triazole Analogues: Optimization toward a Dual Orexin Receptor Antagonist with Improved in vivo Efficacy in Dogs

The orexin system is responsible for regulating the sleep-wake cycle. Suvorexant, a dual orexin receptor antagonist (DORA) is approved by the FDA for the treatment of insomnia disorders. Herein, we report the optimization efforts toward a DORA, where our starting point was (5-methoxy-4-methyl-2-[1,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-[1,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}methanone (6), a compound which emerged from our in-house research program. Compound 6 was shown to be a potent, brain-penetrating DORA with in vivo efficacy similar to suvorexant in rats. However, shortcomings from low metabolic stability, high plasma protein binding (PPB), low brain free fraction (fu brain), and low aqueous solubility, were identified and hence, compound 6 was not an ideal candidate for further development. Our optimization efforts addressing the above-mentioned shortcomings resulted in the identification of (4-chloro-2-[1,2,3]triazol-2-yl-phenyl)-{(S)-2-methyl-2-[5-(2-trifluoromethoxy-phenyl)-4H-[1,2,4]triazol-3-yl]-pyrrolidin-1-yl}l-methanone (42), a DORA with improved in vivo efficacy compared to 6.

SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS

There is provided a compound of formula (I), wherein L1 to L3, R1 to R4, X, A and B have meanings given in the description, and pharmaceutically acceptable salts, solvates and prodrugs thereof, which compounds are useful as antagonists of the orexin-1 and orexin-2 receptors or as selective antagonists of the orexin-1 receptor, and thus, in particular, in the treatment or prevention of inter alia substance dependence, addiction, anxiety disorders, panic disorders, binge eating, compulsive disorders, impulse control disorders, cognitive impairment and Alzheimer's disease.

AZETIDINE AMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS

The present invention relates to azetidine amide derivatives derivatives of formula (I) wherein rings A1 A2 and A3 are as described in the description, to pharmaceutically acceptable salts thereof, to their preparation, to